At the end of MRF/magnet treatments (day 5 of magnet or equivalent to day 7 after HA-Tg-CD8(+) T cell transfer), we determined the fraction of activated tumor-specific CD8(+) T cells homing to the tumor by evaluating for CD8(+)-tetramer-HA+-CD25+ T cells using flow cytometry. The gene discussed is CD8A; the disease is neoplasm.